Full Press Release Details
Announces Launch of PluraPathTM,
a Real-Time, Portable, Water Pathogen Detection System
ORANGE, NJ, January 9, 2020 - Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high
performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced
that it has formally launched PluraPathTM, the only commercially available portable water pathogen detection system
designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample, in
approximately one hour.
recognition of the large market need and opportunity, we are excited to launch our real-time, portable water pathogen detection
system - PluraPathTM," said Daron Evans, President and CEO of Nephros. "Often finding ourselves present
during pathogen outbreaks, we recognized the need for faster, actionable data. Every hour of delay increases patient risk. Additionally,
solely focusing on legionella misses additional pathogens that can contribute to making patients sick. Our PluraPathTM
system evaluates up to 15 separate pathogens, including legionella, pseudomonas, shigella, salmonella, mycobacterium, E. coli.,
norovirus and other potentially dangerous bacterial and viral pathogens."
we will be working with our strategic distributors to provide capability demonstrations to medical facilities across the country.
The combination of rational, regimented pathogen testing, actively managed water disinfection programs, and the risk-based placement
of point-of-use filtration provides enhanced protection for patients from the risks and illnesses associated with waterborne pathogens."
PluraPathTM system uses quantitative polymerase chain reaction (qPCR) technology to provide estimated colony forming
units per milliliter (CFU/ml) information to infection control teams on a real-time basis. Each assay has been developed to target
specific DNA or RNA segments of the target pathogens. The system leverages Nephros's proprietary ultrafiltration technology
to concentrate the water sample and to decrease the lower limit of detection of pathogens in a 1 liter water sample.
expects real-time data from the PluraPathTM to enable infection control teams to quickly assess potential risks throughout
a medical facility, allowing teams to dynamically deploy resources and disinfection efforts during water pathogen outbreaks. Additionally,
when used in conjunction with gold-standard lab-based testing methodologies, PluraPathTM can support the routine testing
prescribed by each facility's water management plan.
are pleased at the performance of our system to detect the presence of pathogens as low as 10 CFU/ml," said Dr. Kimothy
Smith, Vice President of Pathogen Diagnostic Products. "Combined with our unique sample preparation step, we can identify
pathogen levels that are below standard action levels for potable water. PluraPath will enable our customers to evaluate
and monitor the biome' of their building's water systems in a way not currently available without significantly
greater time and expense. We look forward to working with our authorized Nephros ultrafilter distributors to integrate the PluraPathTM
system into their customers' water management plan activities."
information, including a white paper about the Nephros PluraPathTM system can be found at www.nephros.com/pathogen.
Please contact your authorized Nephros distributor to schedule an informational webinar or an on-site demonstration of the Nephros
is a commercial stage company that develops and sells high performance water purification products and pathogen detection systems
to the medical device and commercial markets. Nephros ultrafilters and pathogen detection systems are used in hospitals and medical
clinics to assess and reduce the infection risks from waterborne pathogens (e.g., Legionella, Pseudomonas) in showers, sinks,
and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of endotoxins
and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients.
filters, including AETHER brand filters, improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up
in downstream equipment. Nephros and AETHER products are used in the health care, food service, hospitality, and convenience
more information about Nephros, please visit the company's website at www.nephros.com.
release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements
regarding the PluraPath system capabilities, marketability and sensitivities; and other statements that are not historical
facts, including statements which may be accompanied by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts," "estimates,"
"aims," "believes," "hopes," "potential" or similar words. Actual results could
differ materially from those described in these forward-looking statements due to certain factors, including changes in business,
economic and competitive conditions, lack of acceptance of the PluraPathTM system or other delays in a wide rollout
of the system, and the availability of financing or other capital when needed. These and other risks and uncertainties are detailed
in Nephros's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2018. Nephros does not undertake any responsibility to update the forward-looking statements in this